MENGENAI EPISOD INI
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
Uploaded 19-08-21
https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e1.htm?s_cid=mm7034e1_w
New study from New York
First to assess vaccine protection against coronavirus infection in delta times
Data for New York May 3 to July 25
N = 10.5 million
Modest drop in vaccine effectiveness against lab confirmed infection
May 3, 91.7%
July 25, 79.8%
But
Age adjusted effectiveness against hospitalizations
May 3, 91.9% to 95.3%
July 25, 91.9% to 95.3%
Factors
Delta up from 2% to 80%
Widespread relaxations
Implications
Currently authorized vaccines have high effectiveness against COVID-19 hospitalization,
but effectiveness against new cases appears to have declined in recent months
these findings support the implementation of a layered approach centered on vaccination, as well as other prevention strategies
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
N = 85,593 weekly reports
mRNA vaccines
https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e3.htm?s_cid=mm7034e3_w
Effectiveness against infection declined in nursing homes as delta increased
March, 75%
June, 53%
Vaccination for visitors and staff is crucial,
additional doses of COVID-19 vaccine might be considered for nursing home and long-term care facility residents
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
N = 1,129 diagnosed patients
https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e2.htm?s_cid=mm7034e2_w
Analysis of patients at 21 hospitals
After 2 doses of mRNA vaccine
Across 18 states
Substantial protection against hospitalizations
No decline in protection against hospitalization over 24 weeks
Effectiveness was steady at 86% percent
Immunocompetent adults, 90% protection
Remained constant during delta surge
At 2 to 12 weeks after second dose, 86%
At 13 to 24 weeks after second dose, 84%
CDC director Rochelle Walensky
https://www.washingtonpost.com/health/2021/08/18/covid-vaccine-effectiveness/
Examining numerous cohorts through the end of July and early August, three points are now very clear
First, vaccine-induced protection against SARS-CoV-2 infection begins to decrease over time.
Second, vaccine effectiveness against severe disease, hospitalization and death remains relatively high.
And third, vaccine effectiveness is generally decreased against the delta variant
Learn more about your ad choices. Visit megaphone.fm/adchoices
Learn more about your ad choices. Visit megaphone.fm/adchoices
